Short-term use of rofecoxib increases the risk for adverse cardiovascular events
This article has no abstract so we have provided the first paragraph of the full text.
Inhibition of cyclo-oxygenase 2 might slow the progression of colorectal cancer, but might also increase the risk of adverse cardiovascular events. The cyclo-oxygenase 2 inhibitor rofecoxib was withdrawn worldwide in 2004 after a large trial demonstrated that patients receiving this drug were at an elevated risk of cardiovascular thrombotic events. Kerr et al. have now analyzed data from the VICTOR trial of rofecoxib in patients who had undergone curative surgery for colorectal cancer in order to evaluate the cardiovascular risks associated with the short-term use of this drug to prevent disease recurrence. Patients were randomized to receive either 25 mg/day rofecoxib or placebo.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.